The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions.
Phytomed Plus
; 1(3): 100043, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1087227
ABSTRACT
Background:
Several recent studies have stated that glycyrrhizin and licorice extract are present in most traditional Chinese medicine formulas used against SARS-CoV-2 in China. Significant data are showing that glycyrrhizin and licorice extract have multiple beneficial activities in combating most features of SARS-CoV-2.Purpose:
The aim of current review was to highlight recent progresses in research that showed the evidence of the potential use of glycyrrhizin and licorice extract against COVID-19.Methodology:
We have reviewed the information published from 1979 to October 2020. These studies demonstrated the effects , use and safety of glycyrrhizin and icorice extract against viral infections,bacterial infections, inflammatory disorders of lung ( in vitro and in vivo). These studies were collated through online electronic databases research (Academic libraries as PubMed, Scopus, Web of Science and Egyptian Knowledge Bank).Results:
Pooled effect size of articles provides information about the rationale for using glycyrrhizin and licorice extract to treat COVID-19. Fifty studies demonstrate antiviral activity of glycyrrhizin and licorice extract. The most frequent mechanism of the antiviral activity is due to disrupting viral uptake into the host cells and disrupting the interaction between receptor- binding domain (RBD) of SARS-COV2 and ACE2 in recent articles. Fifty studies indicate that glycyrrhizin and licorice extract have significant antioxidant, anti-inflammatory and immunomodulatory effects. Twenty five studies provide evidence for the protective effect of glycyrrhizin and licorice extract against inflammation-induced acute lung injury and cardiovascular disorders.Conclusion:
The current study showed several evidence regarding the beneficial effects of glycyrrhizin and licorice extract in combating COVID-19. More randomized clinical trials are needed to obtain a precise conclusion.
18ß-GA, 18ß-glycyrrhetinic acid; : ACE2, angiotensin-converting enzyme 2; ALI, acute lung injury; ARDS, acute Respiratory Distress Syndrome; Acute lung injury protector; COVID-19; COVID-19, Coronavirus disease 2019; COX-2, cyclooxygenase-2; DCs, dendritic cells; Gl, glycyrrhizin; Glycyrrhizin and licorice extract;Antiviral and antimicrobial, Anti-inflammatory and antioxidant; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HMGB1, high-mobility group box 1; IL, interleukin; Immunododulator; MAPKs, mitogen-activated protein kinases; MERS, Middle East respiratory syndrome; MR, mineralocorticoid receptor; MRSA, Methicillin-resistant Staphylococcus aureus; NO, nitric oxide; RBD, receptor-binding domain; ROS, reactive oxygen species; S, Spike; SARS, severe acute respiratory syndrome; TCM, traditional Chinese medicine; TLR, toll-like receptor; TMPRSS2, type 2 transmembrane serine protease; TNF-α, tumor necrosis factor alpha; h, hour; iNOS, inducible nitric oxide synthase; licorice extract, LE
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Topics:
Traditional medicine
Language:
English
Journal:
Phytomed Plus
Year:
2021
Document Type:
Article
Affiliation country:
J.phyplu.2021.100043
Similar
MEDLINE
...
LILACS
LIS